Kura Oncology, Inc. (KURA)

NMS – Real Time Price. Currency in USD

9.94

+0.01 (0.10%)

At close: Aug 12, 2026, 4:00 PM EDT

9.85

-0.09 (-0.91%)

After-hours: Aug 12, 2026, 4:14 PM EDT

10.08.2026

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –

07.08.2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 3, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

05.08.2026

Kura Oncology to Report Second Quarter Financial Results

SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026. Kura's management will host a webcast and conference call at 4:30 p.m.

Videos

No Data

There is no data to display

Press releases

10.08.2026

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –

07.08.2026

Kura Oncology, Inc. (KURA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kura Oncology, Inc. (KURA)

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter Financial Results

Videos

No Data

Press releases

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter Financial Results

Videos

No Data

Press releases

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Kura Oncology, Inc. (KURA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kura Oncology, Inc. (KURA)

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter Financial Results

Videos

No Data

Press releases

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter Financial Results

Videos

No Data

Press releases

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)